

**LACHMAN CONSULTANT SERVICES, INC.**  
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590  
(516) 222-6222 • FAX (516) 683-1887

11 17 04 APR -5 10:11

April 2, 2004

**OVERNIGHT COURIER 4/2/04**


Division of Dockets Management  
Food and Drug Administration (HFA-305)  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

**Withdrawal of Citizen Petition Docket No. 2004P-0125/CP1**

Dear Sir or Madam:

The above referenced petition was submitted on March 11, 2004 under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act, and in accordance with 21 CFR 10.30 on behalf of a client requesting the Commissioner of the Food and Drug Administration to declare that the drug product Sertraline Hydrochloride Tablets in strengths of 150 mg and 200 mg are suitable for submission in an abbreviated new drug application (ANDA). We respectfully request that this petition be considered as withdrawn.

Sincerely,

 PK

Robert W. Pollock  
Lachman Consultant Services, Inc.  
Vice President  
1600 Stewart Avenue  
Westbury, NY 11590

RWP/pk

cc: Emily Thakur (Office of Generic Drugs)

R03P4093

2004P- 0125

WDL 1